Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Reduction of Phosphatidylserine Exposure through Copper Chelation Leads to Reduced Fibrin Deposition After Laser Induced Vascular Injury In Vivo.

Reema Jasuja, PhD, Hans-Ulrich Pauer, Regan T Baird, Bruce Furie, MD, Barbara Furie

Blood (2009) 114 (22): 3049.

https://doi.org/10.1182/blood.V114.22.3049.3049

Published: 2009

Journal Articles

Copper Deficiency Remains An Underappreciated Cause of Ineffective Hematopoiesis

Amelia Langston, MD, Jessica Neely, PA, Leonard Heffner, D. Griffith, Martha Arellano, MD, Gregory Esper, MD, Morgan L. McLemore, MD, Thomas Ziegler, MD, Christine Kempton, MD, Rajni Sinha, MD, H. Jean Khoury, MD, Elliott Winton

Blood (2008) 112 (11): 3094.

https://doi.org/10.1182/blood.V112.11.3094.3094

Published: 2008

Journal Articles

Results from the Phase I Portion of a Phase I/II Study of ATN-224 and Bortezomib for Patients with Multiple Myeloma Relapsed from or Refractory to Bortezomib

James R. Berenson, MD, Thomas Ervin, MD, Ralph V. Boccia, MD, Olcay Batuman, MD, Regina Swift, RN, Christina DiLauro Abaya, BA, Andrew P. Mazar, PhD, Gilad S. Gordon, MD, Steven D. Reich, MD, Jennifer A. Callahan, BA

Blood (2008) 112 (11): 5185.

https://doi.org/10.1182/blood.V112.11.5185.5185

Published: 2008

Journal Articles

Early Biomarkers for the Anti-Angiogenic and Anti-Tumor Activity of the Superoxide Dismutase 1 (SOD1) Inhibitor Tetrathiomolybdate.

M.J. Braunstein, E. Smith, C. Timucin, F. Doñate, J.C. Juarez, M. Burnett, M. Manuia, D.E. Shaw, A.P. Mazar, O. Batuman

Blood (2007) 110 (11): 4214.

https://doi.org/10.1182/blood.V110.11.4214.4214

Published: 2007

Journal Articles

Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients (pts) with Advanced Hematologic Malignancies.

James R. Berenson, MD, Ralph Vincent Boccia, MD, Asad Bashey, MD PhD, Alexandra M. Levine, MD, Omer N. Koc, MD, Jennifer A. Callahan, Andrew P. Mazar, PhD, Steven D. Reich, MD

Blood (2006) 108 (11): 2593.

https://doi.org/10.1182/blood.V108.11.2593.2593

Published: 2006

NARROW

Reduction of Phosphatidylserine Exposure through Copper Chelation Leads to Reduced Fibrin Deposition After Laser Induced Vascular Injury In Vivo.

Copper Deficiency Remains An Underappreciated Cause of Ineffective Hematopoiesis

Results from the Phase I Portion of a Phase I/II Study of ATN-224 and Bortezomib for Patients with Multiple Myeloma Relapsed from or Refractory to Bortezomib

Early Biomarkers for the Anti-Angiogenic and Anti-Tumor Activity of the Superoxide Dismutase 1 (SOD1) Inhibitor Tetrathiomolybdate.

Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients (pts) with Advanced Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Reduction of Phosphatidylserine Exposure through Copper Chelation Leads to Reduced Fibrin Deposition After Laser Induced Vascular Injury In Vivo.

Copper Deficiency Remains An Underappreciated Cause of Ineffective Hematopoiesis

Results from the Phase I Portion of a Phase I/II Study of ATN-224 and Bortezomib for Patients with Multiple Myeloma Relapsed from or Refractory to Bortezomib

Early Biomarkers for the Anti-Angiogenic and Anti-Tumor Activity of the Superoxide Dismutase 1 (SOD1) Inhibitor Tetrathiomolybdate.

Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients (pts) with Advanced Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only